Feray Akbas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Feray Akbas has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Hanife Usta Atmaca
Saglik Bilimleri University, Istanbul Training and Research Hospital
14 shared publications - Vahit Can Çavdar
Department of Internal Medicine, Istanbul Training and Research Hospital, University of Health Sciences, Istanbul, Turkey
5 shared publications - Dilek Yazici
Department of Endocrinology and Metabolism, Koc University Faculty of Medicine, Istanbul, Turkey
2 shared publications Hanife Usta Atmaca
Department of Internal Medicine, Istanbul Training and Research Hospital, University of Health Sciences, Istanbul, Turkey
2 shared publicationsHasan Zerdali
Department of Internal Medicine, Istanbul Training and Research Hospital, University of Health Sciences, Istanbul, Turkey
2 shared publications- Mehmet Emin Pişkinpaşa2 shared publications
Latest Publications
- 30 October 2026
- Published by Galenos Yayinevi in Istanbul Medical Journal
Beyond Weight Loss: The Promise and Predicament of Incretin-Based Therapies
Beyond Weight Loss: The Promise and Predicament of Incretin-Based Therapies - Istanbul Medical Journal
- 30 October 2026
- Published by Galenos Yayinevi in Istanbul Medical Journal
Beyond Weight Loss: The Promise and Predicament of Incretin-Based Therapies
Beyond Weight Loss: The Promise and Predicament of Incretin-Based Therapies - Istanbul Medical Journal
- 3 August 2026
- Published by Galenos Yayinevi in Istanbul Medical Journal
Lifestyle Medicine: From Adjunct to Core Internal Medicine Practice
Lifestyle Medicine: From Adjunct to Core Internal Medicine Practice - Istanbul Medical Journal
- 3 August 2026
- Published by Galenos Yayinevi in Istanbul Medical Journal
Lifestyle Medicine: From Adjunct to Core Internal Medicine Practice
Lifestyle Medicine: From Adjunct to Core Internal Medicine Practice - Istanbul Medical Journal
- Open Access
- 7 March 2026
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 26 (1)
Association of serum androgen levels with Framingham Cardiovascular Risk Score in individuals with obesity
Obesity is strongly associated with increased cardiovascular morbidity and mortality. Although traditional risk factors are incorporated into widely used c
- 7 March 2026
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 26 (1)
Open AccessAssociation of serum androgen levels with Framingham Cardiovascular Risk Score in individuals with obesity
Obesity is strongly associated with increased cardiovascular morbidity and mortality. Although traditional risk factors are incorporated into widely used c
- 1 December 2025
- Published by SAGE Publications in Metabolic Syndrome and Related Disorders
- Vol. 23 (10) , 440-447
Unveiling the Silent Threat: Metabolic Dysfunction-Associated Steatotic Liver Disease Risk in Young Adults Through Noninvasive Assessment
Background: The global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing, particularly among young adults, posing significant long-term health risks. Early identification of at-risk individuals is crucial for timely intervention and prevention of liver fibrosis. This study aimed to evaluate the prevalence of MASLD in young adults aged 18–30 years and assess the utility of noninvasive fibrosis scores (fibrosis 4 index, AST-to-platelet ratio index [APRI], Hepamet fibrosis score) in risk stratification. Methods: A retrospective study was conducted on 327 young adults who attended internal medicine outpatient clinics. The diagnosis of MASLD was established based on imaging findings and the presence of metabolic risk factors. Noninvasive fibrosis assessment was performed using the FIB-4, APRI, and hepamet scores, which were subsequently compared between the MASLD and non-MASLD groups. Statistical analyses included parametric and nonparametric tests, with a significance threshold set at p < 0.05. Results: Among the 327 participants, 36.8% ( n = 120) were diagnosed with MASLD. Patients in the MASLD group exhibited significantly higher FIB-4, APRI, and Hepamet scores compared to those in the non-MASLD group ( p < 0.05). Additionally, the MASLD group had significantly elevated body mass index, blood pressure, fasting glucose, triglyceride levels, and insulin resistance compared to the non-MASLD group ( p < 0.05 for all comparisons). Conclusions: MASLD is highly prevalent among young adults and associated with metabolic risk factors. Noninvasive fibrosis scores provide an effective, accessible tool for early risk assessment and should be integrated into routine clinical practice for young adults to prevent future liver-related complications.
- 1 December 2025
- Published by SAGE Publications in Metabolic Syndrome and Related Disorders
- Vol. 23 (10) , 440-447
Unveiling the Silent Threat: Metabolic Dysfunction-Associated Steatotic Liver Disease Risk in Young Adults Through Noninvasive Assessment
Background: The global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing, particularly among young adults, posing significant long-term health risks. Early identification of at-risk individuals is crucial for timely intervention and prevention of liver fibrosis. This study aimed to evaluate the prevalence of MASLD in young adults aged 18–30 years and assess the utility of noninvasive fibrosis scores (fibrosis 4 index, AST-to-platelet ratio index [APRI], Hepamet fibrosis score) in risk stratification. Methods: A retrospective study was conducted on 327 young adults who attended internal medicine outpatient clinics. The diagnosis of MASLD was established based on imaging findings and the presence of metabolic risk factors. Noninvasive fibrosis assessment was performed using the FIB-4, APRI, and hepamet scores, which were subsequently compared between the MASLD and non-MASLD groups. Statistical analyses included parametric and nonparametric tests, with a significance threshold set at p < 0.05. Results: Among the 327 participants, 36.8% ( n = 120) were diagnosed with MASLD. Patients in the MASLD group exhibited significantly higher FIB-4, APRI, and Hepamet scores compared to those in the non-MASLD group ( p < 0.05). Additionally, the MASLD group had significantly elevated body mass index, blood pressure, fasting glucose, triglyceride levels, and insulin resistance compared to the non-MASLD group ( p < 0.05 for all comparisons). Conclusions: MASLD is highly prevalent among young adults and associated with metabolic risk factors. Noninvasive fibrosis scores provide an effective, accessible tool for early risk assessment and should be integrated into routine clinical practice for young adults to prevent future liver-related complications.
- Open Access
- 17 October 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (42) , e45280
A comparative study of serum levels of glucose and aggression: A cross-sectional study
Diabetes mellitus is a metabolic disorder associated not only with physical complications but also with psychological and behavioral disturbances. Emerging evidence suggests that blood glucose fluctuations may influence mood, impulse control, and aggressive behavior. This prospective, observational study included 278 adult patients (171 with type 2 diabetes and 107 without diabetes) admitted to the Internal Medicine Outpatient Clinic of Istanbul Training and Research Hospital between June and August 2025. Participants completed the Buss–Perry Aggression Questionnaire, which measures physical aggression, verbal aggression, anger, and hostility. Clinical data, including fasting blood glucose, insulin, lipid profile, and glycated hemoglobin (HbA1c) levels, were recorded. Individuals with diabetes were further stratified by HbA1c levels to examine the association between glycemic control and aggression. Aggression scores were significantly higher in patients with diabetes compared to those without ( P < .05), and HbA1c levels positively correlated with Buss–Perry Aggression Questionnaire scores within the diabetes group ( R = 0.549, P < .05). Fasting blood glucose, insulin, total cholesterol, and low-density lipoprotein levels were also elevated in individuals with diabetes. Poor glycemic control was associated with higher aggression levels, potentially reflecting alterations in mood regulation and impulse control. Study limitations include the single-center design, the observational nature, and the short follow-up period, which restrict causal inferences. These findings highlight the importance of comprehensive diabetes care that integrates behavioral assessments alongside metabolic monitoring and suggest the need for further longitudinal research to clarify the relationship between glycemic dysregulation and aggression.
- 17 October 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (42) , e45280
Open AccessA comparative study of serum levels of glucose and aggression: A cross-sectional study
Diabetes mellitus is a metabolic disorder associated not only with physical complications but also with psychological and behavioral disturbances. Emerging evidence suggests that blood glucose fluctuations may influence mood, impulse control, and aggressive behavior. This prospective, observational study included 278 adult patients (171 with type 2 diabetes and 107 without diabetes) admitted to the Internal Medicine Outpatient Clinic of Istanbul Training and Research Hospital between June and August 2025. Participants completed the Buss–Perry Aggression Questionnaire, which measures physical aggression, verbal aggression, anger, and hostility. Clinical data, including fasting blood glucose, insulin, lipid profile, and glycated hemoglobin (HbA1c) levels, were recorded. Individuals with diabetes were further stratified by HbA1c levels to examine the association between glycemic control and aggression. Aggression scores were significantly higher in patients with diabetes compared to those without ( P < .05), and HbA1c levels positively correlated with Buss–Perry Aggression Questionnaire scores within the diabetes group ( R = 0.549, P < .05). Fasting blood glucose, insulin, total cholesterol, and low-density lipoprotein levels were also elevated in individuals with diabetes. Poor glycemic control was associated with higher aggression levels, potentially reflecting alterations in mood regulation and impulse control. Study limitations include the single-center design, the observational nature, and the short follow-up period, which restrict causal inferences. These findings highlight the importance of comprehensive diabetes care that integrates behavioral assessments alongside metabolic monitoring and suggest the need for further longitudinal research to clarify the relationship between glycemic dysregulation and aggression.
- 1 August 2025
- Published by SAGE Publications in Metabolic Syndrome and Related Disorders
- Vol. 23 (6) , 312-318
The Relationship Between Metabolic and Inflammatory Parameters at the Time of Diagnosis and Disease Stage and Prognosis in Patients with Pancreatic Cancer
Introduction: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumor often accompanied by various metabolic abnormalities both before and after clinical diagnosis. Diagnosis at advanced stages significantly increases mortality risk. This study aimed to investigate the potential relationship between metabolic and inflammatory parameters at the time of diagnosis and disease stage, and their impact on prognosis in patients with pancreatic cancer. Materials and Methods: A total of 89 patients (43.8% male, 56.2% female) diagnosed with PDAC were included in the retrospective, single-center study. Disease stages at diagnosis that were categorized as stages 1-2 (resectable) and stages 3-4 (locally advanced and metastatic), height, weight, accompanying diseases, body mass index (BMI), inflammatory parameters (C-reactive protein (CRP), neutrophil/lymphocyte ratio (NLR), and metabolic parameters (glucose, HbA1c %, triglyceride, High-Density Lipoprotein [HDL]-cholesterol, Low-Density Lipoprotein [LDL]-cholesterol) were recorded. These parameters were compared between early and advanced stage patients, and their effect on one-year survival was evaluated. Results: The mean age of the patients was 62.7 years; 45.1% of the patients were in stages 1-2, while 48.3% were in stage 4. The one-year overall mortality rate was 32.6%, and the mortality rate was 52.1% in advanced stage (stages 3-4) patients and 9.8% in early stage (stages 1-2) patients. Mean CRP and NLR levels were significantly higher in patients who died compared to those who survived (7.4 vs. 4.4, p = 0.001; p = 0.000, respectively). Mean HDL-cholesterol level was lower in patients who died compared to survivors (34 mg/dL vs. 47.2 mg/dL, p = 0.001). Mean fasting blood glucose and HbA1c levels were higher in patients who died compared to survivors (167 mg/dL vs. 135 mg/dL, 7.5% vs. 6.6%; p = 0.008; p = 0.037, respectively). There were no significant differences in gender, BMI, presence of co-morbidities, triglyceride, or LDL-cholesterol levels between the groups. Conclusion: Recognizing clinical biomarkers predicting prognosis in PDAC could significantly contribute to disease management.
- 1 August 2025
- Published by SAGE Publications in Metabolic Syndrome and Related Disorders
- Vol. 23 (6) , 312-318
The Relationship Between Metabolic and Inflammatory Parameters at the Time of Diagnosis and Disease Stage and Prognosis in Patients with Pancreatic Cancer
Introduction: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumor often accompanied by various metabolic abnormalities both before and after clinical diagnosis. Diagnosis at advanced stages significantly increases mortality risk. This study aimed to investigate the potential relationship between metabolic and inflammatory parameters at the time of diagnosis and disease stage, and their impact on prognosis in patients with pancreatic cancer. Materials and Methods: A total of 89 patients (43.8% male, 56.2% female) diagnosed with PDAC were included in the retrospective, single-center study. Disease stages at diagnosis that were categorized as stages 1-2 (resectable) and stages 3-4 (locally advanced and metastatic), height, weight, accompanying diseases, body mass index (BMI), inflammatory parameters (C-reactive protein (CRP), neutrophil/lymphocyte ratio (NLR), and metabolic parameters (glucose, HbA1c %, triglyceride, High-Density Lipoprotein [HDL]-cholesterol, Low-Density Lipoprotein [LDL]-cholesterol) were recorded. These parameters were compared between early and advanced stage patients, and their effect on one-year survival was evaluated. Results: The mean age of the patients was 62.7 years; 45.1% of the patients were in stages 1-2, while 48.3% were in stage 4. The one-year overall mortality rate was 32.6%, and the mortality rate was 52.1% in advanced stage (stages 3-4) patients and 9.8% in early stage (stages 1-2) patients. Mean CRP and NLR levels were significantly higher in patients who died compared to those who survived (7.4 vs. 4.4, p = 0.001; p = 0.000, respectively). Mean HDL-cholesterol level was lower in patients who died compared to survivors (34 mg/dL vs. 47.2 mg/dL, p = 0.001). Mean fasting blood glucose and HbA1c levels were higher in patients who died compared to survivors (167 mg/dL vs. 135 mg/dL, 7.5% vs. 6.6%; p = 0.008; p = 0.037, respectively). There were no significant differences in gender, BMI, presence of co-morbidities, triglyceride, or LDL-cholesterol levels between the groups. Conclusion: Recognizing clinical biomarkers predicting prognosis in PDAC could significantly contribute to disease management.
- Open Access
- 22 April 2025
- Published by Springer Nature in Hormones
- Vol. 24 (3) , 671-678
Sexual dysfunction in male patients with obesity: is it still being overlooked?
Introduction: Obesity has been linked to an elevated susceptibility to development of erectile dysfunction, yet the interplay between sex hormone levels, sexual function, and obesity remains unclear. This study aimed to investigate sexual dysfunction among male patients with obesity and to emphasize the importance of recognizing the problem and pursuing solutions. Methods: A total of 60 patients were included in the study (30 patients from the obesity center and 30 patients without obesity as the control group). Assessment of androgen hormone deficiency and erectile dysfunction was conducted through the implementation of AMS and IIEF-5 tests. The questionnaire includes aspects of medical history, demographic features, and lifestyle factors. Comprehensive measurements included BMI, WC, BP, lipid panel, total/free testosterone, sex-hormone-binding-globulin (SHBG), dehydroepiandrosterone-sulfate (DHEAS), fasting blood glucose (FBG), fasting insulin, and HbA1C levels. Results were evaluated using SPSS. Results: The AMS score in the obesity group was significantly lower compared to the group without obesity. The IIEF-5 score did not exhibit a statistically significant difference between the groups. Testosterone, free testosterone, SHBG, and HDL values were lower in the obesity group compared to the group without obesity. Conclusion: Although conducted in a small sample, our findings strongly indicate a positive correlation between obesity and the risk of moderate to severe ED. Most of the time, this condition goes unarticulated, thereby adversely affecting the quality of life for individuals with obesity. Clinicians should pay more attention to patients experiencing sexual dysfunction, especially those with obesity.
- 22 April 2025
- Published by Springer Nature in Hormones
- Vol. 24 (3) , 671-678
Open AccessSexual dysfunction in male patients with obesity: is it still being overlooked?
Introduction: Obesity has been linked to an elevated susceptibility to development of erectile dysfunction, yet the interplay between sex hormone levels, sexual function, and obesity remains unclear. This study aimed to investigate sexual dysfunction among male patients with obesity and to emphasize the importance of recognizing the problem and pursuing solutions. Methods: A total of 60 patients were included in the study (30 patients from the obesity center and 30 patients without obesity as the control group). Assessment of androgen hormone deficiency and erectile dysfunction was conducted through the implementation of AMS and IIEF-5 tests. The questionnaire includes aspects of medical history, demographic features, and lifestyle factors. Comprehensive measurements included BMI, WC, BP, lipid panel, total/free testosterone, sex-hormone-binding-globulin (SHBG), dehydroepiandrosterone-sulfate (DHEAS), fasting blood glucose (FBG), fasting insulin, and HbA1C levels. Results were evaluated using SPSS. Results: The AMS score in the obesity group was significantly lower compared to the group without obesity. The IIEF-5 score did not exhibit a statistically significant difference between the groups. Testosterone, free testosterone, SHBG, and HDL values were lower in the obesity group compared to the group without obesity. Conclusion: Although conducted in a small sample, our findings strongly indicate a positive correlation between obesity and the risk of moderate to severe ED. Most of the time, this condition goes unarticulated, thereby adversely affecting the quality of life for individuals with obesity. Clinicians should pay more attention to patients experiencing sexual dysfunction, especially those with obesity.
- 10 December 2024
- Published by SAGE Publications in Metabolic Syndrome and Related Disorders
Impact of Laboratory-Measured Euthyroid Hashimoto’s Thyroiditis on Reproductive Hormone Profile in Women with Obesity
Introduction: Hashimoto's thyroiditis is a common endocrinological disorder that often coexists with obesity. Thyroid hormones interact with the regulation of sex steroids, and thyroid autoimmunity has a negative impact on female fertility. There are studies showing when euthyroid state is achieved with hormone replacement therapy (HRT), the reproductive hormone profile is improved but they usually compare the reproductive hormones before and after HRT in the same individuals. Studies comparing patients with Hashimoto's thyroiditis in an euthyroid state receiving HRT with individuals having normal thyroid function are limited. Here, it was aimed to search the impact of euthyroid Hashimoto's thyroiditis on reproductive hormone profile in women living with obesity. Materials and Methods: Sixty-one randomly selected female patients with Hashimoto's thyroiditis were included as the case group and 60 patients without Hashimoto's thyroiditis were included as the control group, from our obesity center. The case group included patients who had menstrual cycles and were euthyroid under l-thyroxine treatment for at least 6 months. Data on weight, height, body mass index (BMI), waist circumference (WC), free thyroxine (fT4), thyroid stimulating hormone (TSH), thyroid peroxidase antibody (anti-TPO), cortisol, insulin, prolactin (PRL), follicular stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), progesterone (prog), testosterone (T), and dehydroepiandrosterone sulfate (DHEAS) levels, l-thyroxine treatment dosage (for case group), and accompanying diseases were recorded. The results were evaluated using SPSS. Results: A total of 121 patients were included in the study. Mean age was 41.8 ± 8.5 years in case and 38.6 ± 8.9 years in control group. There was no significant difference in weight, height, BMI, WC, or accompanying diseases between Hashimoto's thyroiditis and control group. fT4, anti-TPO, cortisol levels were higher in Hashimoto's thyroiditis group when compared with control group, but there was no significant difference for TSH, insulin, FSH, LH, E2, prog, T, DHEAS, or PRL. Conclusion: In women living with obesity, it is important to screen for Hashimoto's thyroiditis and achieve euthyroidism through effective LT4 treatment to promote a healthy reproductive system and improve fertility rates.
- 10 December 2024
- Published by SAGE Publications in Metabolic Syndrome and Related Disorders
Impact of Laboratory-Measured Euthyroid Hashimoto’s Thyroiditis on Reproductive Hormone Profile in Women with Obesity
Introduction: Hashimoto's thyroiditis is a common endocrinological disorder that often coexists with obesity. Thyroid hormones interact with the regulation of sex steroids, and thyroid autoimmunity has a negative impact on female fertility. There are studies showing when euthyroid state is achieved with hormone replacement therapy (HRT), the reproductive hormone profile is improved but they usually compare the reproductive hormones before and after HRT in the same individuals. Studies comparing patients with Hashimoto's thyroiditis in an euthyroid state receiving HRT with individuals having normal thyroid function are limited. Here, it was aimed to search the impact of euthyroid Hashimoto's thyroiditis on reproductive hormone profile in women living with obesity. Materials and Methods: Sixty-one randomly selected female patients with Hashimoto's thyroiditis were included as the case group and 60 patients without Hashimoto's thyroiditis were included as the control group, from our obesity center. The case group included patients who had menstrual cycles and were euthyroid under l-thyroxine treatment for at least 6 months. Data on weight, height, body mass index (BMI), waist circumference (WC), free thyroxine (fT4), thyroid stimulating hormone (TSH), thyroid peroxidase antibody (anti-TPO), cortisol, insulin, prolactin (PRL), follicular stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), progesterone (prog), testosterone (T), and dehydroepiandrosterone sulfate (DHEAS) levels, l-thyroxine treatment dosage (for case group), and accompanying diseases were recorded. The results were evaluated using SPSS. Results: A total of 121 patients were included in the study. Mean age was 41.8 ± 8.5 years in case and 38.6 ± 8.9 years in control group. There was no significant difference in weight, height, BMI, WC, or accompanying diseases between Hashimoto's thyroiditis and control group. fT4, anti-TPO, cortisol levels were higher in Hashimoto's thyroiditis group when compared with control group, but there was no significant difference for TSH, insulin, FSH, LH, E2, prog, T, DHEAS, or PRL. Conclusion: In women living with obesity, it is important to screen for Hashimoto's thyroiditis and achieve euthyroidism through effective LT4 treatment to promote a healthy reproductive system and improve fertility rates.
- Open Access
- 14 August 2024
- Published by Springer Nature in BMC Geriatrics
- Vol. 24 (1) , 1-7
Exploring depression, comorbidities and quality of life in geriatric patients: a study utilizing the geriatric depression scale and WHOQOL-OLD questionnaire
The increasing prevalence of depression among older adults is a growing concern. Chronic health conditions, cognitive impairments, and hospitalizations amplify emotional distress and depression levels in this population. Assessing the quality of life is crucial for the well-being of older adults. Our study aimed to examine how comorbidities affect depression and quality of life in geriatric patients in both outpatient and hospital settings. 100 patients (50 from internal medicine outpatient clinic and 50 from internal medicine ward) were included in the study according to inclusion and exclusion criteria. Patients were classified into different age groups (65–74 years, 75–84 years and ≥ 85 years). Data on patients’ location of application, age, sex, living alone or with family status, number of comorbid diseases, types of accompanying diseases were recorded and WHOQOL-OLD and Geriatric Depression Scale (GDS) questionnaires were administered. Results were evaluated using SPSS. The WHOQOL-OLD questionnaire score was higher in the 65–74 age group compared to other groups, but there was no significant difference between outpatient group and hospitalized group. Patients with comorbid diseases had lower WHOQOL-OLD questionnaire scores compared to those without comorbid diseases. In the 75–84 and ≥ 85 age groups, the GDS scores were higher compared to the 65–74 age group. In hospitalized group, GDS scores were higher than outpatient clinic group. In patients with comorbid diseases, GDS scores were higher than the ones without comorbid diseases. Our findings indicate that quality of life is higher among those aged 65–74, with lower incidence of depression compared to other age groups. Hospitalization correlates with higher depression rates but not quality of life. As number of comorbid diseases increases in older adults, the frequency of depression rises and the quality of life declines. Early detection and intervention for depression are crucial for enhancing older adults’ well-being.
- 14 August 2024
- Published by Springer Nature in BMC Geriatrics
- Vol. 24 (1) , 1-7
Open AccessExploring depression, comorbidities and quality of life in geriatric patients: a study utilizing the geriatric depression scale and WHOQOL-OLD questionnaire
The increasing prevalence of depression among older adults is a growing concern. Chronic health conditions, cognitive impairments, and hospitalizations amplify emotional distress and depression levels in this population. Assessing the quality of life is crucial for the well-being of older adults. Our study aimed to examine how comorbidities affect depression and quality of life in geriatric patients in both outpatient and hospital settings. 100 patients (50 from internal medicine outpatient clinic and 50 from internal medicine ward) were included in the study according to inclusion and exclusion criteria. Patients were classified into different age groups (65–74 years, 75–84 years and ≥ 85 years). Data on patients’ location of application, age, sex, living alone or with family status, number of comorbid diseases, types of accompanying diseases were recorded and WHOQOL-OLD and Geriatric Depression Scale (GDS) questionnaires were administered. Results were evaluated using SPSS. The WHOQOL-OLD questionnaire score was higher in the 65–74 age group compared to other groups, but there was no significant difference between outpatient group and hospitalized group. Patients with comorbid diseases had lower WHOQOL-OLD questionnaire scores compared to those without comorbid diseases. In the 75–84 and ≥ 85 age groups, the GDS scores were higher compared to the 65–74 age group. In hospitalized group, GDS scores were higher than outpatient clinic group. In patients with comorbid diseases, GDS scores were higher than the ones without comorbid diseases. Our findings indicate that quality of life is higher among those aged 65–74, with lower incidence of depression compared to other age groups. Hospitalization correlates with higher depression rates but not quality of life. As number of comorbid diseases increases in older adults, the frequency of depression rises and the quality of life declines. Early detection and intervention for depression are crucial for enhancing older adults’ well-being.
- 18 June 2024
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 130, 33-37
Pharmacotherapy for older people with obesity
- 18 June 2024
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 130, 33-37
Pharmacotherapy for older people with obesity